Xevudy Helps GSK Ride Out Depressed Shingrix Sales

But COVID-19 Profits Will Drop In 2022

GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.

The pharma and vaccines-focused New GSK will emerge in mid-2022, and investors want to see an improved growth trajectory. • Source: Alamy

The COVID-19 antibody therapy Xevudy came to GlaxoSmithKline’s rescue in 2021, helping to lift the company’s revenues and profits while sales of its flagship shingles vaccine Shingrix continued to suffer from the pandemic.

Co-developed and marketed with Vir Biotechnology, sales of Xevudy (sotrovimab) reached £958m ($1.29bn) in the year, lifted by contracts...